- Home
- DMF vs TLSI Comparison
DMF vs TLSI Comparison
Compare DMF & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMF
- TLSI
- Stock Information
- Founded
- DMF 1988
- TLSI 2010
- Country
- DMF United States
- TLSI United States
- Employees
- DMF N/A
- TLSI N/A
- Industry
- DMF Finance/Investors Services
- TLSI Medical Specialities
- Sector
- DMF Finance
- TLSI Health Care
- Exchange
- DMF Nasdaq
- TLSI Nasdaq
- Market Cap
- DMF 149.5M
- TLSI 158.0M
- IPO Year
- DMF N/A
- TLSI N/A
- Fundamental
- Price
- DMF $7.14
- TLSI $5.77
- Analyst Decision
- DMF
- TLSI Strong Buy
- Analyst Count
- DMF 0
- TLSI 6
- Target Price
- DMF N/A
- TLSI $11.75
- AVG Volume (30 Days)
- DMF 60.7K
- TLSI 40.4K
- Earning Date
- DMF 01-01-0001
- TLSI 03-27-2025
- Dividend Yield
- DMF 2.66%
- TLSI N/A
- EPS Growth
- DMF N/A
- TLSI N/A
- EPS
- DMF 0.15
- TLSI N/A
- Revenue
- DMF N/A
- TLSI $26,891,000.00
- Revenue This Year
- DMF N/A
- TLSI $61.29
- Revenue Next Year
- DMF N/A
- TLSI $53.21
- P/E Ratio
- DMF $45.13
- TLSI N/A
- Revenue Growth
- DMF N/A
- TLSI 67.90
- 52 Week Low
- DMF $5.37
- TLSI $3.50
- 52 Week High
- DMF $6.79
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- DMF 48.80
- TLSI 68.94
- Support Level
- DMF $7.10
- TLSI $5.40
- Resistance Level
- DMF $7.18
- TLSI $5.82
- Average True Range (ATR)
- DMF 0.05
- TLSI 0.24
- MACD
- DMF 0.00
- TLSI 0.01
- Stochastic Oscillator
- DMF 50.00
- TLSI 89.19
About DMF BNY Mellon Municipal Income Inc.
BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.